Cargando…
Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy
Specific targets of cellular immunity in human premalignancy are largely unknown. Monoclonal gammopathy of undetermined significance (MGUS) represents a precursor lesion to myeloma (MM). We show that antigenic targets of spontaneous immunity in MGUS differ from MM. MGUS patients frequently mount a h...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118551/ https://www.ncbi.nlm.nih.gov/pubmed/17389240 http://dx.doi.org/10.1084/jem.20062387 |
_version_ | 1782141052556148736 |
---|---|
author | Spisek, Radek Kukreja, Anjli Chen, Lin-Chi Matthews, Phillip Mazumder, Amitabha Vesole, David Jagannath, Sundar Zebroski, Henry A. Simpson, Andrew J.G. Ritter, Gerd Durie, Brian Crowley, John Shaughnessy, John D. Scanlan, Matthew J. Gure, Ali O. Barlogie, Bart Dhodapkar, Madhav V. |
author_facet | Spisek, Radek Kukreja, Anjli Chen, Lin-Chi Matthews, Phillip Mazumder, Amitabha Vesole, David Jagannath, Sundar Zebroski, Henry A. Simpson, Andrew J.G. Ritter, Gerd Durie, Brian Crowley, John Shaughnessy, John D. Scanlan, Matthew J. Gure, Ali O. Barlogie, Bart Dhodapkar, Madhav V. |
author_sort | Spisek, Radek |
collection | PubMed |
description | Specific targets of cellular immunity in human premalignancy are largely unknown. Monoclonal gammopathy of undetermined significance (MGUS) represents a precursor lesion to myeloma (MM). We show that antigenic targets of spontaneous immunity in MGUS differ from MM. MGUS patients frequently mount a humoral and cellular immune response against SOX2, a gene critical for self-renewal in embryonal stem cells. Intranuclear expression of SOX2 marks the clonogenic CD138(−) compartment in MGUS. SOX2 expression is also detected in a proportion of CD138(+) cells in MM patients. However, these patients lack anti-SOX2 immunity. Cellular immunity to SOX2 inhibits the clonogenic growth of MGUS cells in vitro. Detection of anti-SOX2 T cells predicts favorable clinical outcome in patients with asymptomatic plasmaproliferative disorders. Harnessing immunity to antigens expressed by tumor progenitor cells may be critical for prevention and therapy of human cancer. |
format | Text |
id | pubmed-2118551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21185512007-12-13 Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy Spisek, Radek Kukreja, Anjli Chen, Lin-Chi Matthews, Phillip Mazumder, Amitabha Vesole, David Jagannath, Sundar Zebroski, Henry A. Simpson, Andrew J.G. Ritter, Gerd Durie, Brian Crowley, John Shaughnessy, John D. Scanlan, Matthew J. Gure, Ali O. Barlogie, Bart Dhodapkar, Madhav V. J Exp Med Articles Specific targets of cellular immunity in human premalignancy are largely unknown. Monoclonal gammopathy of undetermined significance (MGUS) represents a precursor lesion to myeloma (MM). We show that antigenic targets of spontaneous immunity in MGUS differ from MM. MGUS patients frequently mount a humoral and cellular immune response against SOX2, a gene critical for self-renewal in embryonal stem cells. Intranuclear expression of SOX2 marks the clonogenic CD138(−) compartment in MGUS. SOX2 expression is also detected in a proportion of CD138(+) cells in MM patients. However, these patients lack anti-SOX2 immunity. Cellular immunity to SOX2 inhibits the clonogenic growth of MGUS cells in vitro. Detection of anti-SOX2 T cells predicts favorable clinical outcome in patients with asymptomatic plasmaproliferative disorders. Harnessing immunity to antigens expressed by tumor progenitor cells may be critical for prevention and therapy of human cancer. The Rockefeller University Press 2007-04-16 /pmc/articles/PMC2118551/ /pubmed/17389240 http://dx.doi.org/10.1084/jem.20062387 Text en Copyright © 2007, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Articles Spisek, Radek Kukreja, Anjli Chen, Lin-Chi Matthews, Phillip Mazumder, Amitabha Vesole, David Jagannath, Sundar Zebroski, Henry A. Simpson, Andrew J.G. Ritter, Gerd Durie, Brian Crowley, John Shaughnessy, John D. Scanlan, Matthew J. Gure, Ali O. Barlogie, Bart Dhodapkar, Madhav V. Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy |
title | Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy |
title_full | Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy |
title_fullStr | Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy |
title_full_unstemmed | Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy |
title_short | Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy |
title_sort | frequent and specific immunity to the embryonal stem cell–associated antigen sox2 in patients with monoclonal gammopathy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118551/ https://www.ncbi.nlm.nih.gov/pubmed/17389240 http://dx.doi.org/10.1084/jem.20062387 |
work_keys_str_mv | AT spisekradek frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT kukrejaanjli frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT chenlinchi frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT matthewsphillip frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT mazumderamitabha frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT vesoledavid frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT jagannathsundar frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT zebroskihenrya frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT simpsonandrewjg frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT rittergerd frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT duriebrian frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT crowleyjohn frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT shaughnessyjohnd frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT scanlanmatthewj frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT gurealio frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT barlogiebart frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy AT dhodapkarmadhavv frequentandspecificimmunitytotheembryonalstemcellassociatedantigensox2inpatientswithmonoclonalgammopathy |